Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
09/2003
09/24/2003CN1444558A Novel N-(2-phenyl-3-aminopropyl) naphtamides
09/24/2003CN1444481A Protease inhibitors
09/24/2003CN1443571A Bone growth factor injection and its preparation method
09/24/2003CN1443569A Preparation method of cordyceps biological activity multivitamin intensifying agent
09/24/2003CN1443568A Preparation method of ganoderma biological activity multivitamin intesifying agent
09/24/2003CN1443566A Eshu oil
09/24/2003CN1443565A Heiguidou oil
09/24/2003CN1443563A Huoluo oil
09/24/2003CN1443559A Tongluoning Chinese medicine
09/24/2003CN1443551A Chinese medicine preparation for curing hyperosteogeny and its preparation method
09/24/2003CN1443550A Chinese medicine for curing necrosis of femoral head
09/24/2003CN1122037C Thiophene [2,3,-d] hybar X compound and its preparing method, use and medical composition containing it
09/23/2003US6624202 Inhibitors of copper-containing amine oxidases
09/23/2003US6624199 Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units
09/23/2003US6624192 Diacetylrhein containing aloe-emodin components is subjected to a liquid-liquid partitioning between a polar organic solvent which is only partly miscible with water and an aqueous phase of pH 6.5 to 7.5 and the diacetylrhein is
09/23/2003US6624185 Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism
09/23/2003US6624164 1,3-dihydro-2H-indol-2-one derivatives, preparation method and pharmaceutical composition containing them
09/23/2003US6624157 Antitumor agents
09/23/2003US6624148 Synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of
09/23/2003US6624147 Inhibitors of prenylated pyrophosphate consuming enzymes
09/23/2003US6624144 Matrix metalloproteinase inhibitors and down-regulators
09/23/2003US6623934 For isolation of proteins that may be used to induce bone and/or cartilage or other connective tissue formation, and in wound healing and tissue repair
09/23/2003US6623755 Pharmaceutical tablets
09/23/2003CA2244196C Dihydrobenzofuran compounds useful as anti-inflammatory agents
09/18/2003WO2003076639A1 Osteoclast differentiation inhibitors
09/18/2003WO2003076458A2 Selective dipeptide inhibitors of kallikrein
09/18/2003WO2003076447A1 An optically acitve pyridine derivative and a medicament containing the same
09/18/2003WO2003076438A1 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
09/18/2003WO2003076436A1 Derivatives of 4- (imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity
09/18/2003WO2003076435A1 Pyrimidine compounds
09/18/2003WO2003076434A1 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
09/18/2003WO2003076433A1 Pyrimidine compounds
09/18/2003WO2003076432A1 Benzodiazepine-substituted piperidines for utilization in the treatment of cardiovascular diseases
09/18/2003WO2003076430A1 Amino-derivatives as novel inhibitors of histone deacetylase
09/18/2003WO2003076424A1 Macrocyclic compounds useful as pharmaceuticals
09/18/2003WO2003076421A1 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
09/18/2003WO2003076417A2 Oxo-azabicyclic compounds
09/18/2003WO2003076416A1 Oxo azabicyclic compounds
09/18/2003WO2003076407A1 Novel chalcone derivatives and uses thereof
09/18/2003WO2003076406A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies
09/18/2003WO2003076402A1 Therapeutic agent for pain
09/18/2003WO2003076401A1 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
09/18/2003WO2003076400A1 New inhibitors of histone deacetylase
09/18/2003WO2003076393A1 Salts of nateglinide
09/18/2003WO2003075945A2 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis
09/18/2003WO2003075929A1 Inhibitors of histone deacetylase
09/18/2003WO2003075923A1 Vdac regulator
09/18/2003WO2003075922A1 Nitrogen monoxide synthase inhibitors
09/18/2003WO2003075893A1 Controlled release dosage forms
09/18/2003WO2003075857A2 Amino-methyl substituted tetracycline compounds
09/18/2003WO2003075847A2 NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
09/18/2003WO2003075836A2 Cathepsin cysteine protease inhibitors
09/18/2003WO2003075741A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
09/18/2003WO2003075685A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
09/18/2003WO2003075670A1 Treatment and prevention of inflammatory disorders
09/18/2003WO2003059283A3 Compounds for blocking androgen receptors
09/18/2003WO2003059252A3 Use of a novel cell surface protease from group b streptococcus
09/18/2003WO2003053915A3 Compounds for the treatment of inflammatory disorders
09/18/2003WO2003053368A3 Chalcone derivatives and their use to treat diseases
09/18/2003WO2003048122A3 Inhibitors of cytosolic phospholipase a2
09/18/2003WO2003046135A3 Osteopontin-related compositions and methods
09/18/2003WO2003035007A3 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
09/18/2003WO2002100901A3 Determination of bone-sialoprotein in bodily fluids for oncological problems
09/18/2003WO2002083700B1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
09/18/2003WO2002077174A3 Human cytokine receptor
09/18/2003WO2002066646A3 Neurotransmission-associated proteins
09/18/2003WO2002062750A9 Cannabinoid receptor ligands
09/18/2003WO2002059308A3 Method of diagnosing and treating cartilage disorders
09/18/2003WO2002050287A3 Multifunctional protease inhibitors and their use in treatment of disease
09/18/2003US20030176707 Process for preparing integrin antagonist intermediate
09/18/2003US20030176686 Diagnosis, therapy; animal growth regulators; controlling cell differentiation; antiiinflammatory agents, antihistamines, Crohn's disease, anticancer agents, autoimmune disease
09/18/2003US20030176647 Antibodies to OCIF-binding molecules
09/18/2003US20030176642 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
09/18/2003US20030176509 Methods and products related to 16-HETE analogs
09/18/2003US20030176498 Inhibitors of alpha4mediated cell adhesion
09/18/2003US20030176497 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments
09/18/2003US20030176496 Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof
09/18/2003US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer
09/18/2003US20030176484 Administering to the mammal an effective amount of a GSK-3 beta (glycogen synthase kinase-3 beta) to promote bone formation and treat bone metabolic diseases such as osteoporosis
09/18/2003US20030176476 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
09/18/2003US20030176463 For therapy of disease states resulting from angiogenesis; can be administered orally
09/18/2003US20030176455 Inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing with an effective amount of a rapamycin
09/18/2003US20030176453 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/18/2003US20030176445 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists
09/18/2003US20030176430 For therapy and prophylaxis of Tachykinin-mediated diseases
09/18/2003US20030176422 Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
09/18/2003US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
09/18/2003US20030176397 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
09/18/2003US20030176383 Antisense modulation of p38 mitogen activated protein kinase expression
09/18/2003US20030176379 Useful in the administration of a drug, therapy
09/18/2003US20030176363 For therapy of T lymphocyte mediated inflammatory diseases in animals and man
09/18/2003US20030176341 For use as an anti-viral, anti-tumour or immunomodulatory agent
09/18/2003US20030176331 Having therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins; for therapy of cancer
09/18/2003US20030176315 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction
09/18/2003US20030175881 Nucleic acids encoding (poly) peptides having chips activity
09/18/2003US20030175855 Human sdf-5 protein and compositions
09/18/2003US20030175680 Methods of treating and preventing bone loss
09/18/2003US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents
09/18/2003US20030175373 Osteoporosis therapy; plant extract
09/18/2003US20030175334 Phospholipid bodies and use thereof in medical treatment
1 ... 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 ... 820